BC Week In Review | Sep 19, 2016
Company News

Lundbeck neurology, generics news

The EU General Court upheld a decision from the European Commission to fine Lundbeck for anticompetitive activity related to Lundbeck’s antidepressant Celexa citalopram. The court said that the commission correctly found that Lundbeck’s agreements with...
BC Innovations | Apr 21, 2016
Targets & Mechanisms

Structural SERT-ainty

The publication this month of the crystal structure of the serotonin transporter unquestionably marked a technical watershed, and solved long-asked questions about why similar compounds bind the protein differently. Historically, the target revolutionized depression, spawning...
BC Week In Review | Apr 18, 2016
Company News

Epic Pharma, Humanwell Healthcare Group, PuraCap Pharmaceutical LLC deal

Humanwell and PuraCap will acquire generic company Epic for $550 million. Epic’s assets include generics of cardiovascular drug amlodipine, marketed as Norvasc by Pfizer Inc. (NYSE:PFE, New York, N.Y.); depression drug citalopram, marketed as Celexa...
BC Innovations | Jul 17, 2014
Distillery Techniques

Technology: Markers

Approach Summary Licensing status Publication and contact information Markers Monitoring microRNA-1202 (miR-1202) expression to predict antidepressant treatment response Cell culture and patient sample studies suggest monitoring miR-1202 expression could help predict response to antidepressants in...
BC Innovations | Jun 19, 2014
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Serotonin (5-HT) transporter (SLC6A4; SERT) Mouse and human studies suggest selective serotonin reuptake inhibitors (SSRIs) could help prevent AD. In three-month-old mice...
BC Week In Review | Sep 9, 2013
Company News

Lundbeck neurology news

H. Lundbeck filed an appeal in the EU General Court of a June 19 decision from the European Commission to fine Lundbeck €93.8 million ($124 million) for anticompetitive activity related to Lundbeck's antidepressant Celexa citalopram....
BC Week In Review | Jun 24, 2013
Company News

Actavis, Lundbeck, Merck KGaA, Ranbaxy, Xellia Pharmaceuticals A/S, Zoetis neurology news

The European Commission fined H. Lundbeck €93.8 million ($125 million) after ruling that deals with four generic companies for Lundbeck's antidepressant Celexa citalopram violated competition law. The commission said that after Lundbeck's basic patents covering...
BioCentury | Nov 5, 2012
Strategy

Racing to rebuild AZ

AstraZeneca plc 's new CEO Pascal Soriot has not yet detailed his vision for the company, but comments last month on his first call with investors coupled with an early move to halt the company's...
BC Week In Review | Jul 30, 2012
Company News

Lundbeck neurology news

H. Lundbeck said it received from the European Commission a statement of objections regarding deals with four generic companies for Lundbeck's antidepressant Celexa citalopram. Lundbeck, which did not disclose the contents of the statement of...
BioCentury | Dec 5, 2011
Strategy

Lundbeck psyched up

H. Lundbeck A/S 's deal with Otsuka Pharmaceutical Co. Ltd. for two late-stage programs is designed to take the Danish pharma beyond replacing patent-related revenue losses, giving it products to establish a foothold in the...
Items per page:
1 - 10 of 143